Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficiency of BCMA-PD1-CART in Relapsed/Refractory Multiple Myeloma
NCT04162119Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2019
- Primary completion
- Oct 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BCMA-PD1-CART in multiple myeloma (MM), sponsored by Chinese PLA General Hospital. Primary endpoint: Incidence of Treatment-related Adverse Events at 3 years. Status: unknown.
02
Drugs
BCMA-PD1-CART
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04162119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162119.